Tempest Therapeutics (TPST) Common Equity (2011 - 2026)
Tempest Therapeutics (TPST) posted Common Equity of $6.7 million for Q4 2025, up 5.07% sequentially from $6.3 million in Q3 2025, and down 65.14% YoY from $19.1 million in Q4 2024.
Tempest Therapeutics (TPST) Common Equity (2011 - 2026) Analysis & Trends
Tempest Therapeutics has reported Common Equity for 15 years, with the latest figure at $6.7 million in Q4 2025.
- Quarterly Common Equity fell 65.14% year-over-year to $6.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.7 million (down 65.14% YoY) and the FY2025 annual result came in at $6.7 million, down 65.14% from the prior year.
- Common Equity grew to $6.7 million in Q4 2025 per TPST's latest filing, from $6.3 million in the prior quarter.
- Over five years, Common Equity peaked at $48.1 million in Q2 2021 and troughed at -$74.0 million in Q1 2021.
- A 5-year average of $11.0 million and a median of $14.2 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity sank 104.44% in 2023, then soared 1062.77% in 2024.
- Over 5 years, Common Equity stood at $36.1 million in 2021, then sank by 49.85% to $18.1 million in 2022, then soared by 47.8% to $26.8 million in 2023, then fell by 28.55% to $19.1 million in 2024, then sank by 65.14% to $6.7 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $6.7 million, $6.3 million, and $9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | -1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.09 Mn |
| Dec 31, 2025 | 6.67 Mn |
| Sep 30, 2025 | 6.35 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Mar 31, 2025 | 11.13 Mn |
| Dec 31, 2024 | 19.13 Mn |
| Sep 30, 2024 | 11.46 Mn |
| Jun 30, 2024 | 16.94 Mn |
| Mar 31, 2024 | 20.63 Mn |
| Dec 31, 2023 | 26.77 Mn |
| Sep 30, 2023 | -1.19 Mn |
| Jun 30, 2023 | 5.01 Mn |
| Mar 31, 2023 | 10.97 Mn |
| Dec 31, 2022 | 18.11 Mn |
| Sep 30, 2022 | 26.77 Mn |
| Jun 30, 2022 | 34.93 Mn |
| Mar 31, 2022 | 29.36 Mn |
| Dec 31, 2021 | 36.12 Mn |
| Sep 30, 2021 | -43.54 Mn |
| Jun 30, 2021 | 48.11 Mn |